James Chih‐Hsin Yang

Zhejiang International Studies University — China

Medicine · Health Sciences

140h-index109.0kcitations1.2kworks11.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(869), Lung Cancer Research Studies(300), Colorectal Cancer Treatments and Studies(278), Lung Cancer Diagnosis and Treatment(224), Cancer Immunotherapy and Biomarkers(127)

Publications1.2k total

Supplementary Methods, Tables, Figures from Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, <i>MET</i>-Amplified Non–Small Cell Lung Cancer: TATTON
2025Open Access
Enhancing Salient Object Detection in RGB-D Videos via Tri-modal Complementary Fusion
The Visual Computer·2025
Metabolic benefits of 1,3-diacylglycerol in type 2 diabetes mellitus and its association with gut microbiota-derived SCFAs-GPR41-GLP-1 signaling
Food & Function·2025
Factors Associated With Sedentary Behavior Reduction in Older Adults Based on the Capability, Opportunity, Motivation, and Behavior Model: A Multicenter Cross-Sectional Study
Journal of the American Medical Directors Association·2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
Journal of Clinical Oncology·2025Open Access
Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant NSCLC with EGFR Inhibitor Resistance Due to &lt;i&gt;MET&lt;/i&gt; Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary PLS from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant NSCLC with EGFR Inhibitor Resistance Due to &lt;i&gt;MET&lt;/i&gt; Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant NSCLC with EGFR Inhibitor Resistance Due to &lt;i&gt;MET&lt;/i&gt; Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant NSCLC with EGFR Inhibitor Resistance Due to &lt;i&gt;MET&lt;/i&gt; Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Table S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant NSCLC with EGFR Inhibitor Resistance Due to &lt;i&gt;MET&lt;/i&gt; Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Table S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant NSCLC with EGFR Inhibitor Resistance Due to &lt;i&gt;MET&lt;/i&gt; Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Table S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant NSCLC with EGFR Inhibitor Resistance Due to &lt;i&gt;MET&lt;/i&gt; Amplification: INSIGHT Final Analysis
2025Open Access
Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant NSCLC with EGFR Inhibitor Resistance Due to &lt;i&gt;MET&lt;/i&gt; Amplification: INSIGHT Final Analysis
2025Open Access
Author response for "Metabolic benefits of 1,3-diacylglycerol in type 2 diabetes mellitus and its association with gut microbiota-derived SCFAs-GPR41-GLP-1 signaling"
2025
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer
Lung Cancer·2025
Author response for "Metabolic benefits of 1,3-diacylglycerol in type 2 diabetes mellitus and its association with gut microbiota-derived SCFAs-GPR41-GLP-1 signaling"
2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
Clinical Lung Cancer·2025
Survival with Osimertinib plus Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine·2025· 18 cited
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC
Journal of Biomedical Science·2025· 1 citedOpen Access
P3.12.40 Safety and Patient-Reported Outcomes With Tepotinib in Patients With METex14 Skipping NSCLC: =3-Years Follow-Up of VISION
Journal of Thoracic Oncology·2025
page 1 of 60Next →

Frequent Co-authors

Steven A. Rosenberg(22), Richard M. Sherry(16), Suzanne L. Topalian(13), Udai S. Kammula(12), Nicholas P. Restifo(11), Mark E. Dudley(10), Donald E. White(10), Tony Mok(9), John R. Wunderlich(9), Marybeth S. Hughes(8), Richard E. Royal(8), Paul F. Robbins(7), Douglas J. Schwartzentruber(7), Claudia A. Seipp(7), Sharon Mavroukakis(7), Vera Hirsh(6), Wu‐Chou Su(6), Pasi A. Jänne(6), Chee Khoon Lee(6), Lecia V. Sequist(5)